Scotiabank lowered the firm’s price target on Janux Therapeutics (JANX) to $36 from $41 and keeps a Sector Perform rating on the shares. The firm cut its price target on the stock based on the lower probability of success for its Phase 1 trial of JANX007, which the firm believes is “more appropriate” for a Phase 1 cancer drug with limited patient exposure, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JANX:
- Promising Pipeline and Strategic Advancements Justify Buy Rating for Janux Therapeutics Inc
- Positive Buy Rating for Janux Therapeutics Inc. Driven by Promising Clinical Data and Strong Financial Position
- Buy Rating Affirmed for Janux Therapeutics: Promising Clinical Data and Superior Efficacy of Lead Program JANX007
- Janux Therapeutics Inc: Undervalued Growth Potential Amid Recent Stock Pullback
- Janux Therapeutics reports Q1 EPS (38c), consensus (39c)